MedTrace Logo

Non-Invasive Biomarkers in Prostate Cancer Disease Management

NCT06144619 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2026-02-09

No results posted yet for this study

Summary

This study is an observational retrospective/ prospective study with diagnosed low/intermediate risk (no-surgery) \& high risk (surgery) prostate cancer that are eligible and willing to undergo standard of care (SOC) assessment, annually along with biopsies, bio-fluid collection. Participants will obtain genomic and histological evaluation on their biopsied samples. Study follows SOC collection with additional body fluid collection (blood, urine). Biopsy/surgery will not require additional sample collection

Conditions

Interventions

GENETIC

Genomic and Histological Evaluation

Participants will obtain genomic and histological evaluation on their biopsied samples. (Follows SOC)

Sponsors & Collaborators

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Yoganand Balagurunathan, PhD · Moffitt Cancer Center

  • Julio Pow-Sang, MD · Moffitt Cancer Center

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-21
Primary Completion
2029-01-31
Completion
2029-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06144619 on ClinicalTrials.gov